Dyamic contrast enhanced MRI (DCE-MRI) pharmacodynamic (PD) study of sorafenib in metastatic renal cell carcinoma (RCC): Results of a randomized, phase II trial

被引：0
|
作者：
hahn, O. M. [1 ]
Yeng, C. [1 ]
Medved, M. [1 ]
Karczmar, G. [1 ]
Kistner, E. [1 ]
Manchen, B. [1 ]
Mitchell, M. [1 ]
Karrison, T. [1 ]
Ratain, M. [1 ]
Stadler, W. M. [1 ]
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3545
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Dyamic contrast-enhanced magnetic resonance imaging pharmacodynamic study of sorafenib in metastatic renal cell carcinoma: Preliminary results of a randomized, phase II trial.
    Yang, C.
    Hahn, O.
    Medved, M.
    Karczmar, G.
    Kistner, E.
    Karrison, T.
    Manchen, B.
    Mitchell, M.
    Ratain, M.
    Stadler, W. M.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2007, 55 (02) : S364 - S364
  • [2] Dynamic contrast enhanced-MRI (DCE-MRI) as a pharmacodynamic biomarker for pazopanib (PZ) in metastatic renal carcinoma (RC).
    Sweis, Randy F.
    Medved, Milica
    Towey, Shannon
    Karczmar, Greg S.
    Oto, Aytekin
    Szmulewitz, Russell Zelig
    O'Donnell, Peter H.
    Fishkin, Paul A. S.
    Stadler, Walter Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] PHASE I STUDY OF PAZOPANIB (PAZ) IN HEPATOCELLULAR CARCINOMA (HCC): DETERMINATION OF MTD AND EVALUATION OF CLINICAL ACTIVITY, PHARMACOKINETICS (PK), AND PHARMACODYNAMIC (PD) CHANGES IN DYNAMIC CONTRAST ENHANCED MRI (DCE-MRI)
    Yau, Thomas
    Chen, Pei-Jer
    Curtis, C. Martin
    Murphy, Philip S.
    Suttle, A. Benjamin
    Arumugham, Thangam
    Hodge, Jeffrey P.
    Dar, Mohammed M.
    Poon, Ronnie T.
    [J]. HEPATOLOGY, 2009, 50 (04) : 1124A - 1125A
  • [4] Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
    Flaherty, Keith T.
    Rosen, Mark A.
    Heitjan, Daniel F.
    Gallagher, Maryann L.
    Schwartz, Brian
    Schnall, Mitchell D.
    O'Dwyer, Peter J.
    [J]. CANCER BIOLOGY & THERAPY, 2008, 7 (04) : 496 - 501
  • [5] Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
    Motzer, Robert J.
    Rini, Brian I.
    McDermott, David F.
    Redman, Bruce G.
    Kuzel, Timothy M.
    Harrison, Michael R.
    Vaishampayan, Ulka N.
    Drabkin, Harry A.
    George, Saby
    Logan, Theodore F.
    Margolin, Kim A.
    Plimack, Elizabeth R.
    Lambert, Alexandre M.
    Waxman, Ian M.
    Hammers, Hans J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) : 1430 - 1437
  • [6] Contrasting vascular response to sunitinib as measured by DCE-CT, DCE-MRI, and DCE-US in renal cell carcinoma (RCC) patients (pts)
    Hudson, John M.
    Williams, Ross
    Milot, Laurent M.
    Bailey, Colleen
    Kiss, Alex
    Atri, Mostafa
    Stanisz, Greg J.
    Burns, Peter N.
    Bjarnason, Georg A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Microbubble ultrasound (DCE-US) compared to DCE-MRI and DCE-CT for the assessment of vascular response to sunitinib in renal cell carcinoma (RCC).
    Bjarnason, G. A.
    Williams, R.
    Hudson, J. M.
    Bailey, C.
    Lee, C. R.
    Lloyd, B. A.
    Kandel, S.
    Ebos, J. M.
    Kiss, A.
    Kerbel, R. S.
    Milot, L. M.
    Atri, M.
    Stanisz, G. J.
    Burns, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Phase I study of Pazopanib (PAZ) in Hepatocellular Carcinoma (HCC): evaluation of clinical activity, Pharmacokinetics (PK), and Dynamic Contrast Enhanced MRI (DCE-MRI)
    Yau, C. C.
    Chen, P.
    Curtis, C.
    Murphy, P.
    Parker, G.
    Suttle, A.
    Arumugham, T.
    Hodge, J.
    Dar, M.
    Poon, R.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 122 - 122
  • [9] A randomized phase II study of thalidomide with or without erythropoietin (EPO) in metastatic renal cell carcinoma (RCC).
    Famoyin, C
    Byrnes, C
    Roberts, S
    Gollob, J
    Atkins, M
    Mier, J
    Ko, YJ
    Gautam, S
    McDemott, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 443S - 443S
  • [10] Phase-II trial of thalidomide for patients with metastatic renal cell carcinoma (RCC).
    Green, D
    Meza-Junco, J
    Arce, C
    Chavez-Macgregor, M
    de la Peña, R
    Sotomayor, M
    Gabilondo, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 443S - 443S
12345